Navigation Links
Pufferfish neurotoxin may serve as treatment for cancer therapy related pain
Date:6/26/2013

HACKENSACK, N.J. (June 26, 2013)- Researchers at the Brain and Spine Institute at John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, are studying a possible alternative to side effect-ridden opioid-based medications to treat cancer-related pain. The active ingredient for the treatment is Tetrodotoxin, a neurotoxin found in pufferfish.

"Chemotherapy-induced neuropathic pain is a serious debilitating condition that occurs in over 40 percent of patients receiving chemotherapy," said Principal Investigator Samuel Goldlust, M.D., Co-Chief of the Brain and Spine Institute at John Theurer Cancer Center. "Tetrodotoxin has been found to be 3,000 times more potent than morphine without the negative side effects of opioids."

Caused by damage to neurons in the peripheral nervous system, chemotherapy-induced neuropathic pain is one of the most common reasons that cancer patients stop their treatment early, negatively affecting patient outcomes. For some patients, the symptoms persist after chemotherapy for months, years, or even indefinitely.

Until recently, chemotherapy-induced neuropathic pain, was treated primarily with opioids, anti-depressants or drugs primarily used to treat seizures. Scientists have learned more recently of the importance of sodium channels in the conduction of pain signals from peripheral nerves to the brain. Derived from a neurotoxin found in pufferfish, Tetrodotoxin targets sodium channels in the patient's peripheral nervous system. By blocking the sodium channels, Tetrodotoxin limits the conduction of pain signals to the central nervous system, offering relief from pain related to damage caused by chemotherapy.

Many species of marine pufferfish contain a large amount of Tetrodotoxin in their skin and tissues as an evolutionary adaptation to reduce predation. The dose used in this clinical trial needed for pain relief is approximately 300 times less than the total found in one fish.

"WEX is committed to developing a new class of non-opioid analgesics," said Mr. Walter Korz, VP, & General Manager of WEX Pharmaceuticals. "We are honored to have an institution such as John Theurer Cancer Center at HackensackUMC participating with Dr. Goldlust serving as Principal Investigator for this groundbreaking multicenter phase II clinical trial using Terodotoxin."

"Novel approaches to treatment are accelerating cancer care at an unprecedented rate," said Andre Goy M.D., M.S., Chairman and Director, and Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates. "We believe it is important that our researchers are actively involved in shaping the future of cancer care through clinical trials such as this one."

"Clinical trials allow us to continue offering the most advanced treatments options to our patients to improve outcomes and quality of life," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor, and Vice President of Cancer Services and President of Regional Cancer Care Associates, LLC.


'/>"/>

Contact: Jon Byington
jon.byington@porternovelli.com
212-601-8208
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. MS researchers determine that brain reserve independently protects against cognitive decline in MS
2. University of New England and Partners Celebrate Opening of Portland Community Health Center at Riverton June 20 for Underserved Populations
3. Effective Environmental Services Launch New Websites to Serve Customers
4. Allsup Observes National HIV Testing Day June 27
5. Merrill DataSite Releases New Comments: Cash Reserves and M&A Options
6. New Water Select® Showerhead Valve Conserves Water & Saves Money
7. On The Road to Better Health – Newark Residents to Be Served by New Mobile Health Center
8. PD-like sleep and motor problems observed in α-synuclein mutant mice
9. Fuseideas Expands to Serve Midwest Clients
10. Allsup Observes National Disability Professionals Week – June 10-14
11. Newport Board Group, a National Business Advisory Firm of CEOs That Serves the Middle Market, Issues Guidance for Companies Considering a Sale in 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of ... while encouraging readers to sign up as an organ donor for the 123,000 people ... , An organ donor can save up to 8 saves through organ donation and ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to ... "I thought that if the nebulizer had a more child-friendly design, then children would ... He developed the patent-pending NEBY to avoid the need to deliver medication via a ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health ... . , Results of the comparative usability study demonstrate that a dictation-based method ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has ... 2016 Top Workplaces National Standard. To learn ... ... (PRNewsFoto/Diplomat Pharmacy, Inc.) ... an employee survey administered by WorkplaceDynamics, LLC, a research firm specializing ...
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... Research and Markets has announced the addition of the "Global ... - Forecast to 2025" report to their offering. ... , , ... a CAGR of around 3.2% from 2015 to 2025. Some of ... extracellular microelectrode arrays and intracellular microelectrodes, research in left-to-right shunt detection ...
Breaking Medicine Technology: